Cited by 501Vitamin C and Antioxidants ResearchOvarian cancer diagnosis and treatmentCancer, Hypoxia, and Metabolism

High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian Cancer and Reduced Toxicity of Chemotherapy

Ma, Yan, Chapman, Julia, Levine, Mark, Polireddy, Kishore, Drisko, Jeanne, Chen, Qi·2014·Science Translational Medicine

Abstract

Pharmacological use of ascorbate (vitamin C) enhanced chemosensitivity of ovarian cancer in preclinical models and reduced chemotherapy-associated toxicity in patients.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3007154

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • When used with chemotherapy, ascorbate shielded healthy tissues from treatment-related toxicity.

    “A significant number of human studies consistently show that ascorbate treatment improved quality of life for patients with cancer, and in combination therapy, ascorbate protected normal tissues from toxicity caused by chemotherapy114.”

    From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [114]

  • Patients with cancer who received ascorbate reported better quality of life.

    “A significant number of human studies consistently show that ascorbate treatment improved quality of life for patients with cancer, and in combination therapy, ascorbate protected normal tissues from toxicity caused by chemotherapy114.”

    From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [114]

  • Preclinical and clinical work indicates that high-dose vitamin C may raise the effectiveness and lower the toxicity of some standard chemotherapies when given together in ovarian cancer patients.

    “This paper shows in its preclinical and clinical studies that high-dose vitamin C can potentially increase the efficacy and reduce the toxicities of certain conventional chemotherapies when used in combination to treat patients with ovarian cancer.”

    From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [114]

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ma, Y., Chapman, J., Levine, M., Polireddy, K., Drisko, J., & Chen, Q.
Affiliations
  • University of Kansas Medical Center (US)
  • National Institutes of Health (US)
Corresponding author
  • Drisko, Jeanne
  • Chen, Qi
Venue
Science Translational Medicine
Published
2014-02-05
Volume
6
Issue
222
Pages
222ra18-222ra18
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W2139847043
Cited by
501
References
57
Citations by year
2026: 23 · 2025: 29 · 2024: 44 · 2023: 55 · 2022: 50 · 2021: 51 · 2020: 42 · 2019: 44 · 2018: 53 · 2017: 38 · 2016: 28 · 2015: 23 · 2014: 21
FWCI
34.15
Type
journal article
Language
en
Open access
closed
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Vitamin C and Antioxidants Research
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords
vitamin C, ovarian cancer, chemosensitization, carboplatin, paclitaxel, chemotherapy toxicity, pro-oxidant activity, hydrogen peroxide, DNA damage, ATP depletion, mTOR inhibition, combination therapy, cancer cell death
MeSH terms
Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Ascorbic Acid, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Synergism, Female, Humans, Infusions, Parenteral, Ovarian Neoplasms, Carboplatin, Cell Death, Paclitaxel, Xenograft Model Antitumor Assays, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review